Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Receivables - Other: 2019-2024

Historic Receivables - Other for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $1.6 million.

  • Pharming Group N.V's Receivables - Other fell 25.59% to $1.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.6 million, marking a year-over-year decrease of 25.59%. This contributed to the annual value of $1.6 million for FY2024, which is 25.59% down from last year.
  • As of FY2024, Pharming Group N.V's Receivables - Other stood at $1.6 million, which was down 25.59% from $2.1 million recorded in FY2023.
  • Over the past 5 years, Pharming Group N.V's Receivables - Other peaked at $2.4 million during FY2021, and registered a low of $1.1 million during FY2022.
  • Its 3-year average for Receivables - Other is $1.6 million, with a median of $1.6 million in 2024.
  • In the last 5 years, Pharming Group N.V's Receivables - Other skyrocketed by 166.60% in 2020 and then tumbled by 52.73% in 2022.
  • Yearly analysis of 5 years shows Pharming Group N.V's Receivables - Other stood at $2.3 million in 2020, then rose by 2.52% to $2.4 million in 2021, then crashed by 52.73% to $1.1 million in 2022, then spiked by 92.03% to $2.1 million in 2023, then decreased by 25.59% to $1.6 million in 2024.